An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor*

Eph receptor tyrosine kinases represent promising disease targets because they are differentially expressed in pathologicversus normal tissues. The EphA2 receptor is up-regulated in transformed cells and tumor vasculature where it likely contributes to cancer pathogenesis. To exploit EphA2 as a therapeutic target, we used phage display to identify two related peptides that bind selectively to EphA2 with high affinity (submicromolarK D values). The peptides target the ligand-binding domain of EphA2 and compete with ephrin ligands for binding. Remarkably, one of the peptides has ephrin-like activity in that it stimulates EphA2 tyrosine phosphorylation and signaling. Furthermore, this peptide can deliver phage particles to endothelial and tumor cells expressing EphA2. In contrast, peptides corresponding to receptor-interacting portions of ephrin ligands bind weakly and promiscuously to many Eph receptors. Bioactive ephrin mimetic peptides could be used to selectively deliver agents to Eph receptor-expressing tissues and modify Eph signaling in therapies for cancer, pathological angiogenesis, and nerve regeneration.

[1]  Martin Lackmann,et al.  Crystal structure of an Eph receptor–ephrin complex , 2001, Nature.

[2]  J G Flanagan,et al.  The ephrins and Eph receptors in neural development. , 1998, Annual review of neuroscience.

[3]  T. Hunter,et al.  Receptor protein-tyrosine kinases and their signal transduction pathways. , 1994, Annual review of cell biology.

[4]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[5]  Erkki Ruoslahti,et al.  Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature , 2001, Arthritis research.

[6]  J. Flanagan,et al.  Identification and cloning of ELF-1, a developmentally expressed ligand for the Mek4 and Sek receptor tyrosine kinases , 1994, Cell.

[7]  Michael Dohn,et al.  Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis , 2001, Oncogene.

[8]  E. Ruoslahti,et al.  Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Gram,et al.  Binding Epitope of Somatostatin Defined by Phage-Displayed Peptide Libraries , 1995, Bio/Technology.

[10]  E Ruoslahti,et al.  Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. , 1999, Biochemistry.

[11]  E. Robertson,et al.  The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development , 1994, Mechanisms of Development.

[12]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[13]  A. Reith,et al.  The Eck receptor tyrosine kinase is implicated in pattern formation during gastrulation, hindbrain segmentation and limb development. , 1994, Oncogene.

[14]  M. Kinch,et al.  Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. , 2002, Cancer research.

[15]  J. Ruiz,et al.  Ephrin-A1 is expressed at sites of vascular development in the mouse , 1998, Mechanisms of Development.

[16]  J. Devlin,et al.  Random peptide libraries: a source of specific protein binding molecules. , 1990, Science.

[17]  K. Hirokawa,et al.  Overexpression of protein tyrosine kinases in human esophageal cancer. , 1997, Pathobiology : journal of immunopathology, molecular and cellular biology.

[18]  M. Herlyn,et al.  Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis , 1995, International journal of cancer.

[19]  J. Rhim,et al.  Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway , 2001, Nature Cell Biology.

[20]  Erkki Ruoslahti,et al.  Membrane Dipeptidase Is the Receptor for a Lung-targeting Peptide Identified by in Vivo Phage Display* , 1999, The Journal of Biological Chemistry.

[21]  E. Pasquale,et al.  Eph receptors and ephrin ligands: embryogenesis to tumorigenesis , 2000, Oncogene.

[22]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[23]  C. Myers,et al.  Homeobox B3 Promotes Capillary Morphogenesis and Angiogenesis , 2000, The Journal of cell biology.

[24]  S. Whittemore,et al.  Induction of Eph B3 after Spinal Cord Injury , 1999, Experimental Neurology.

[25]  A. Andres,et al.  Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. , 1994, Oncogene.

[26]  E. Pasquale,et al.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization , 2000, Oncogene.

[27]  M. Kinch,et al.  E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[28]  A. Pandey,et al.  Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. , 1995, Science.

[29]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[30]  E. Pasquale,et al.  Ephrin-A6, a new ligand for EphA receptors in the developing visual system. , 2001, Developmental biology.

[31]  M. Kinch,et al.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells. , 2001, Cancer research.

[32]  R Pasqualini,et al.  A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins , 1995, The Journal of cell biology.

[33]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[34]  Mette A Peters,et al.  Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase , 2002, Journal of cellular biochemistry.

[35]  E Ruoslahti,et al.  Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library , 1994, The Journal of cell biology.

[36]  S. Dunlop,et al.  Expression of ephrin‐A2 in the superior colliculus and EphA5 in the retina following optic nerve section in adult rat , 2001, The European journal of neuroscience.

[37]  D. Bostwick,et al.  Overexpression of the EphA2 tyrosine kinase in prostate cancer , 1999, The Prostate.

[38]  D. Nikolov,et al.  Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2 , 1998, Nature.

[39]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[40]  Sabita Roy,et al.  Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor‐toxin conjugate , 1997, International journal of cancer.

[41]  Franco Weth,et al.  Modulation of EphA Receptor Function by Coexpressed EphrinA Ligands on Retinal Ganglion Cell Axons , 1999, Neuron.

[42]  R. Klein,et al.  The N‐terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling , 1997, The EMBO journal.

[43]  E. Katchalski‐Katzir,et al.  Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Ruoslahti,et al.  Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. , 1993, The Journal of biological chemistry.

[45]  Erkki Ruoslahti,et al.  Targeting the prostate for destruction through a vascular address , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Hendrix,et al.  Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). , 2001, Cancer research.